Radeberg, Germany Clinical Trials

A listing of Radeberg, Germany clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 393 clinical trials
featured
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

www.MyelofibrosisResearch.com Myelofibrosis (MF) is a bone marrow illness that affects blood-forming tissues in the body. MF disturbs the body's normal production of blood cells, causing extensive scarring in the bone marrow. This leads to severe anemia, weakness, fatigue, and an enlarged spleen. The purpose of this study is to assess …

BAG Freiberg-Richter /ID# 221346
 (7.4 away) Contact site
  • 164 views
  • 29 Apr, 2021
  • +224 other locations
featured
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

www.MyelofibrosisResearch.com Myelofibrosis is a type of bone marrow cancer that usually develops slowly and disrupts body's normal production of blood cells. It causes bone marrow scarring, leading to severe anemia that can cause weakness and fatigue. It can also cause a low number of blood-clotting cells called platelets, which increases …

BAG Freiberg-Richter /ID# 221347
 (7.4 away) Contact site
  • 32 views
  • 29 Apr, 2021
  • +148 other locations
featured
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

This is an open-label, monotherapy study of INCB054828 in subjects with myeloid/lymphoid neoplasms with FGFR1 rearrangement.  Subjects will receive a once daily (QD) dose of INCB054828 at 13.5 mg on a 2-week-on–therapy and 1-week-off–therapy schedule.  With Protocol Amendment 3, the administration schedule will be adjusted, and newly enrolled subjects will …

lymphoid malignancy
FGFR1
myeloid neoplasm
Universitaetsklinikum Leipzig
 (6.7 away) Contact site
  • 79 views
  • 14 Dec, 2020
  • +34 other locations
featured
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 (formerly MGA012) in Patients with Advanced Solid Tumors

This study is a Phase 1, open-label, dose escalation and cohort expansion study designed to characterize the safety, tolerability, PK, PD, immunogenicity, and preliminary anti-tumor activity of INCMGA00012 administered IV every two or four weeks in patients with relapsed/refractory, unresectable locally advanced or metastatic solid tumors.  The study consists of …

endometrial carcinoma
cancer
primary cancer
measurable disease
UNIVERSITY CLINIC CARL GUSTAV CARUS, TECHNICAL UNIVERSITY DRESDEN
 (7.4 away) Contact site
  • 229 views
  • 14 Dec, 2020
  • +15 other locations
Driving Pressure During General Anesthesia for Open Abdominal Surgery

The purpose of this international multicenter, patient and outcome-assessor blinded randomized controlled trial is to determine whether the application of an individualized high PEEP strategy, aiming at avoiding an increase in the driving pressure during intraoperative ventilation, protects against the development of postoperative pulmonary complications.

University hospital Carl Gustav Carus
 (8.8 away) Contact site
  • 3 views
  • 29 Jan, 2021
  • +21 other locations
PRISM Study-Pruritus Relief Through Itch Scratch Modulation

To investigate the anti-pruritic efficacy and safety of Nalbuphine ER (NAL ER) tablets in Prurigo Nodularis. Subjects will be randomized to NAL ER (or matching placebo) with the primary endpoint evaluation at Week 14. During the open label extension, subjects who received NAL ER will continue on NAL ER and …

nalbuphine
Study Site 213
 (7.4 away) Contact site
  • 661 views
  • 12 Jun, 2021
  • +85 other locations
Re-evaluation of Optimal Re-synchronisation Therapy in Patients With Chronic Heart Failure

The objective of the study is to demonstrate that in patients with chronic heart failure who receive optimal medical treatment for this condition and have indication for Cardiac Resynchronisation Therapy, the implantation of a pacemaker (index group) is not inferior to defibrillator (control group) with respect to all-cause mortality.

cardiomyopathy
medical therapy
cardiac resynchronization therapy
ejection fraction
Praxisklinik Herz und Gef e
 (5.1 away) Contact site
  • 2 views
  • 16 Jun, 2021
  • +349 other locations
Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

The main purpose of the study is to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with topical treatments.

Galderma Investigational Site
 (8.3 away) Contact site
  • 108 views
  • 01 May, 2021
  • +225 other locations
Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure

The purpose of this study is to evaluate the effect of treatment with omecamtiv mecarbil compared with placebo on exercise capacity as determined by cardiopulmonary exercise testing following 20 weeks of treatment with omecamtiv mecarbil or placebo

Praxisklinik Dresden
 (5.1 away) Contact site
  • 62 views
  • 18 Jun, 2021
  • +80 other locations
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- Early Breast Cancer

Novartis Investigative Site
 (7.4 away) Contact site
  • 211 views
  • 02 Jun, 2021
  • +361 other locations